Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
暂无分享,去创建一个
M. Loh | Zhiguo Chen | R. Larson | M. Liedtke | F. Appelbaum | S. Hunger | M. Tallman | W. Stock | M. Devidas | R. Stone | N. Winick | A. Advani | W. Carroll | E. Raetz | H. Erba | S. Luger | Jennifer L. McNeer | D. Claxton | Jun Yin | K. Laumann | M. Foster | Eric Larsen | Kristin Coffan
[1] W. Stock,et al. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia , 2020, Leukemia & lymphoma.
[2] H. D. de Groot-Kruseman,et al. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Schmiegelow,et al. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Bloomfield,et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.
[5] F. Berthold,et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents , 2018, Haematologica.
[6] M. Oberley,et al. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens , 2018, Pediatric blood & cancer.
[7] T. Klausen,et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia , 2018, Leukemia.
[8] A. Bleyer,et al. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature , 2018, Leukemia & lymphoma.
[9] N. Gökbuget. Treatment of older patients with acute lymphoblastic leukemia. , 2016, Hematology. American Society of Hematology. Education Program.
[10] M. Loh,et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Konopleva,et al. Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen , 2016, American journal of hematology.
[12] B. Leber,et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia , 2014, Leukemia.
[13] L. Vidal,et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric‐inspired regimens: Systematic review and meta‐analysis , 2012, American journal of hematology.
[14] K. Kelly,et al. A randomized, controlled, double‐blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL) , 2010, Cancer.
[15] N. Heerema,et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] H. Dombret,et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Tormo,et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Loh,et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Bloomfield,et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. , 2005, Blood.
[20] John Wu,et al. Blood Coagulation, Fibrinolysis and Cellular Haemostasis , 2022 .
[21] C. Schiffer. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Schmiegelow,et al. Results of NOPHO ALL 2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia , 2022 .